Jerusalem, 25 November, 2025 (TPS-IL) — Innocan Pharma, an Israeli-Canadian company, reported encouraging results from a study testing its long-acting CBD treatment for chronic pain. The research, published in Frontiers in Pharmacology, examined two goats that received injections of the company’s Liposomal Synthetic Cannabidiol (LPT-CBD) every six weeks for 10 months.
The treatment maintained steady CBD levels, improved mobility and quality of life, and showed no adverse effects — including no rise in liver enzymes, a common issue with oral CBD.
Innocan says the findings strengthen the potential for LPT-CBD to become a safe, non-opioid pain therapy for humans, supporting further development in Israel and abroad.